Skip to main content

What new GSK cancer deal shows about pharma market

The announcement that GlaxoSmithKline is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.